SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Hympavzi

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US (since October 2024) and EU (since November 2024), with expanded labels in both regions in mid-2026.
Why 3/10
Hympavzi is already approved and commercialized in both the US and EU with no pending PDUFA or pivotal readout in the next ~12 months. As an approved drug at a company with ~$60B+ in annual revenue, it lacks a hard binary catalyst that could drive a significant share-price move, capping the impact score at 3.
Actionable Insight NEUTRAL

Hympavzi is already approved in both the US and EU for hemophilia A and B with and without inhibitors. No upcoming PDUFA or pivotal readout is scheduled in the next 12 months. The next catalyst to watch would be quarterly sales trajectory and any further label expansion (e.g., younger pediatric patients), but neither is a hard binary event. For a company the size of Pfizer, this drug is unlikely to be a standalone share-price driver.

Price Chart

Loading chart...

Executive Summary

Hympavzi (marstacimab) is Pfizer's once-weekly subcutaneous monoclonal antibody for hemophilia A and B, approved by the FDA in October 2024 and expanded in June 2026 to cover patients ages 6 and older with or without inhibitors. The European Commission also approved it initially in November 2024 and expanded the label in May 2026. It is the first anti-TFPI therapy approved for both hemophilia subtypes. However, it enters a competitive market dominated by Roche's Hemlibra (emicizumab, ~$4-5B in sales) and faces additional competition from Sanofi's Qfitlia and Novo Nordisk's Alhemo. For Pfizer, a company guiding $60.5-62 billion in 2026 revenue, Hympavzi is one product among many and lacks a near-term binary catalyst.

How It Works

Hympavzi is a monoclonal antibody (a lab-made protein) that blocks a natural clotting inhibitor called TFPI (tissue factor pathway inhibitor). By neutralizing TFPI, it helps restore the blood's ability to clot, reducing the risk of bleeding episodes in people with hemophilia A or B. It works independently of the missing clotting factor, so it can be used in patients with or without inhibitors (antibodies that neutralize standard factor replacement therapy). It is given as a once-weekly shot under the skin.

Trial Status

Approved based on the Phase 3 BASIS study (NCT03938792) in hemophilia A or B without inhibitors, and a separate Phase 3 study in patients with inhibitors. An open-label extension study is ongoing. The drug is commercially available in the US and EU.

The Two-Sided Case

▲ Bull Case5
First and only anti-TFPI antibody approved for both hemophilia A and B, with or without inhibitors, giving it a broad label that covers both subtypes.
Once-weekly subcutaneous injection with a pre-filled auto-injector pen offers convenience versus daily or IV alternatives.
Phase 3 BASIS study showed a 93% reduction in bleeds compared to on-demand treatment in patients with inhibitors.
FDA expanded label in June 2026 to include patients ages 6-11 and those with inhibitors, expanding the addressable patient population.
European Commission expanded approval in May 2026 to include inhibitor patients, opening a second major market.
▼ Bear Case4
Faces entrenched competition from Roche's Hemlibra (emicizumab), which generated roughly $4-5 billion in global sales in 2025 and offers less frequent dosing.
Other rebalancing agents are entering the market: Sanofi's Qfitlia and Novo Nordisk's Alhemo are gaining physician adoption, per Spherix Global Insights (April 2026).
List price of $795,600/year before discounts may face payer pushback and access barriers, especially as multiple rebalancing agents compete for formulary placement.
For Pfizer, a company guiding $60.5-62 billion in 2026 revenue, Hympavzi is a small product unlikely to materially move the stock.

Upcoming Catalysts

  • No upcoming PDUFA or pivotal readout identified in the next 12 months.
  • Potential further label expansion to younger pediatric patients (under age 6) could be a future catalyst but no timeline is set.
  • Quarterly sales trajectory and physician adoption data (e.g., Spherix surveys) are the main ongoing metrics to watch.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 13

Hover a chip for the title
1 pfizer.com2 pfizer.com3 healio.com4 businesswire.com5 pfizer.com6 pfizer.com7 hympavzi.pfizerpro.com8 fda.gov9 drugs.com10 spherixglobalinsights.com11 synapse.patsnap.com12 pfizer.com13 msn.com